Together, these results suggest a mechanism that m6A can modulate the efficacy of immunotherapy not only by regulating the number of CD8+ T cells and cytokine production in the tumor microenvironment, but also by achieving high antigen-specific CD8+ T cell antitumor response. Here, CD8A is linked to neoplasm.